Oberweis Asset Management Inc. Buys 50,000 Shares of NeoGenomics, Inc. (NASDAQ:NEO)

Oberweis Asset Management Inc. boosted its position in shares of NeoGenomics, Inc. (NASDAQ:NEO - Free Report) by 7.0% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 768,700 shares of the medical research company's stock after purchasing an additional 50,000 shares during the period. Oberweis Asset Management Inc. owned 0.60% of NeoGenomics worth $12,668,000 at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. Greenhouse Funds LLLP grew its position in NeoGenomics by 5.3% in the 4th quarter. Greenhouse Funds LLLP now owns 4,701,897 shares of the medical research company's stock worth $77,487,000 after purchasing an additional 237,491 shares during the last quarter. Mirova bought a new position in NeoGenomics during the fourth quarter valued at about $1,070,000. MetLife Investment Management LLC raised its holdings in NeoGenomics by 3.5% in the 4th quarter. MetLife Investment Management LLC now owns 77,403 shares of the medical research company's stock valued at $1,276,000 after acquiring an additional 2,596 shares in the last quarter. Dimensional Fund Advisors LP lifted its position in shares of NeoGenomics by 2.3% in the 4th quarter. Dimensional Fund Advisors LP now owns 3,436,858 shares of the medical research company's stock worth $56,645,000 after acquiring an additional 78,211 shares during the period. Finally, First Trust Advisors LP lifted its position in shares of NeoGenomics by 316.9% in the 4th quarter. First Trust Advisors LP now owns 132,180 shares of the medical research company's stock worth $2,178,000 after acquiring an additional 100,475 shares during the period. 98.50% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

NEO has been the subject of a number of analyst reports. Piper Sandler cut their price target on shares of NeoGenomics from $21.00 to $18.00 and set an "overweight" rating for the company in a research note on Wednesday, February 26th. Needham & Company LLC lowered their price target on NeoGenomics from $19.00 to $18.00 and set a "buy" rating on the stock in a research report on Wednesday, February 19th. Bank of America cut their price objective on NeoGenomics from $19.00 to $16.00 and set a "neutral" rating for the company in a report on Wednesday, February 19th. Benchmark downgraded shares of NeoGenomics from a "buy" rating to a "hold" rating in a report on Monday, January 13th. Finally, The Goldman Sachs Group reduced their target price on NeoGenomics from $17.00 to $15.00 and set a "buy" rating on the stock in a report on Thursday, April 17th. Two research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $19.30.

NeoGenomics Price Performance

NASDAQ:NEO traded down $3.26 during mid-day trading on Tuesday, hitting $6.72. 6,239,328 shares of the stock traded hands, compared to its average volume of 992,504. NeoGenomics, Inc. has a 12-month low of $6.68 and a 12-month high of $19.12. The company has a quick ratio of 1.91, a current ratio of 1.98 and a debt-to-equity ratio of 0.38. The company has a market cap of $863.93 million, a PE ratio of -10.80 and a beta of 1.41. The business's 50-day moving average price is $9.74 and its 200 day moving average price is $13.45.

NeoGenomics (NASDAQ:NEO - Get Free Report) last announced its earnings results on Tuesday, April 29th. The medical research company reported ($0.08) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.02) by ($0.06). NeoGenomics had a negative net margin of 11.92% and a negative return on equity of 2.10%. The firm's revenue was up 7.6% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.02) EPS. On average, analysts expect that NeoGenomics, Inc. will post -0.2 EPS for the current fiscal year.

NeoGenomics Company Profile

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.